Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Wilson Therapeutics in connection with its IPO
Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

 Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026

Vinge advises Spotlight Group in connection with offer from Kriptown

 Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

 Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026